---
layout: default
title: Ramucirumab
parent: Model Prediction Only (L5)
nav_order: 665
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ramucirumab: From VEGFR2-Targeted Antiangiogenic Therapy to Uterine Ligament Adenocarcinoma

## One-Sentence Summary

Ramucirumab (DB05578) is a VEGFR2-targeted monoclonal antibody that inhibits tumour angiogenesis; the evidence pack does not record a specific original indication or formal mechanism-of-action text (both flagged as data gaps).
The TxGNN model predicts it may be effective for **uterine ligament adenocarcinoma**, but this is currently a **model-score-only prediction** — **0 clinical trials** and **0 publications** support this specific indication.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack (`original_indications` empty; MOA marked as data gap) |
| Predicted New Indication | Uterine ligament adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (marked as a data gap in the evidence pack). Based on the information that is available in the repurposing rationale, Ramucirumab is a VEGFR2 (vascular endothelial growth factor receptor 2) monoclonal antibody that inhibits tumour angiogenesis — a mechanism class shared with bevacizumab, which is already approved for cervical cancer.

Gynecologic adenocarcinomas, including uterine ligament and cervical adenocarcinoma subtypes, are generally considered to have high angiogenic dependence, which provides a plausible theoretical rationale for anti-VEGFR2 therapy in this setting. However, this link is drawn purely by mechanistic analogy — there is no direct clinical or preclinical data connecting Ramucirumab specifically to uterine ligament adenocarcinoma, and the drug's own original indication record is missing from this evidence pack, so the analogy cannot be cross-checked against its proven use.

Given the rarity and pathological heterogeneity of the predicted indication (and related subtypes ranked #2–#10, all rare cervical/uterine ligament adenocarcinoma variants), the prediction should be treated as a hypothesis-generating signal rather than an evidence-supported candidate at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Ramucirumab is currently **not marketed** in Canada under this evidence pack (`market_status: Not marketed`), with **0 DIN licenses** on record. No product listings are available to summarize.

---

## Cytotoxicity

Ramucirumab is being evaluated exclusively against cancer indications (all top-10 predicted indications are adenocarcinoma subtypes), so this section is included.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (VEGFR2-targeted monoclonal antibody, anti-angiogenic) — inferred from the repurposing rationale text, not from a formal DrugBank category field |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score (99.95%), there is zero clinical trial or literature support for this indication (Evidence Level L5), and a **Blocking**-severity data gap (TFDA labeling/warnings, DG001) prevents even an initial safety screen (S1). The drug is also unmarketed in Canada.

**To proceed, the following is needed:**
- TFDA/regulatory label with warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Confirmed original indication(s) for baseline mechanistic comparison
- Any preclinical or early-phase evidence specific to uterine ligament/cervical adenocarcinoma subtypes before advancing past S0
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

